Tim Wright, Editor, Contract Pharma10.10.18
Earlier this year, at FutureLink Munich 2018, more than 200 pharmaceutical and healthcare executives from 100 companies were polled on a range of topics relating to serialization and the EU’s Falsified Medicines Directive (FMD).
Over 1,600 responses were submitted providing insight into the industry’s biggest challenges and opportunities with regards to serialization. Here, Staffan Widengren, director of corporate projects at Recipharm, and Jean-Marie Aulnette, vice president EMEA, TraceLink, discuss the key findings in the report, “EU FMD Readiness and the Future of Digital Drug Supply,” in an exclusive Q&A with Contract Pharma.
Contract Pharma: The report revealed that 28% of respondents said onboarding of contract manufacturing organizations (CMOs) was the most complex component of a track and trace program with 8 in 10 respondents believing most small CMOs are underprepared. Why is onboarding such a significant challenge?
Staffan Widengren
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
